JP2021520372A5 - - Google Patents

Info

Publication number
JP2021520372A5
JP2021520372A5 JP2020554235A JP2020554235A JP2021520372A5 JP 2021520372 A5 JP2021520372 A5 JP 2021520372A5 JP 2020554235 A JP2020554235 A JP 2020554235A JP 2020554235 A JP2020554235 A JP 2020554235A JP 2021520372 A5 JP2021520372 A5 JP 2021520372A5
Authority
JP
Japan
Prior art keywords
cancer
leukemia
compound according
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554235A
Other languages
English (en)
Japanese (ja)
Other versions
JP7387630B2 (ja
JP2021520372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/053443 external-priority patent/WO2019207538A1/en
Publication of JP2021520372A publication Critical patent/JP2021520372A/ja
Publication of JP2021520372A5 publication Critical patent/JP2021520372A5/ja
Application granted granted Critical
Publication of JP7387630B2 publication Critical patent/JP7387630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554235A 2018-04-26 2019-04-26 Smarca2/4分解剤としてのピリダジン誘導体 Active JP7387630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841015818 2018-04-26
IN201841015818 2018-04-26
PCT/IB2019/053443 WO2019207538A1 (en) 2018-04-26 2019-04-26 Pyridazine derivatives as smarca2/4 degraders

Publications (3)

Publication Number Publication Date
JP2021520372A JP2021520372A (ja) 2021-08-19
JP2021520372A5 true JP2021520372A5 (cg-RX-API-DMAC7.html) 2022-05-09
JP7387630B2 JP7387630B2 (ja) 2023-11-28

Family

ID=68295093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554235A Active JP7387630B2 (ja) 2018-04-26 2019-04-26 Smarca2/4分解剤としてのピリダジン誘導体

Country Status (7)

Country Link
US (2) US12371426B2 (cg-RX-API-DMAC7.html)
EP (1) EP3784665A4 (cg-RX-API-DMAC7.html)
JP (1) JP7387630B2 (cg-RX-API-DMAC7.html)
CN (1) CN112771038B (cg-RX-API-DMAC7.html)
CA (1) CA3118354A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104495YA (cg-RX-API-DMAC7.html)
WO (1) WO2019207538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
WO2020160192A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN114502543A (zh) * 2019-05-24 2022-05-13 拜欧斯瑞克斯公司 靶向蛋白化合物、其药物组合物及治疗应用
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3150354A1 (en) * 2019-09-12 2021-03-18 Muralidhara Ramachandra METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS
EP4054724A4 (en) * 2019-10-28 2023-12-27 C4 Therapeutics, Inc. BIFUNCTIONAL CONNECTIONS
CN114728936A (zh) * 2019-10-29 2022-07-08 豪夫迈·罗氏有限公司 用于治疗癌症的双功能化合物
CN110790746B (zh) * 2019-11-18 2020-10-30 南京恒通医药开发有限公司 一种利用微通道反应器连续化制备泊马度胺的合成工艺
US11679109B2 (en) * 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CA3167166A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
MX2022009308A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de estos.
WO2021163302A1 (en) * 2020-02-12 2021-08-19 Dana-Farber Cancer Institute, Inc. Compounds, compositions, and methods for protein degradation
JP7508578B2 (ja) * 2020-04-06 2024-07-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
TWI918648B (zh) 2020-05-06 2026-03-21 美商新銳思生物製藥股份有限公司 造血前驅細胞激酶之雙官能降解劑及其治療用途
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
MX2023001445A (es) * 2020-08-04 2023-05-08 Aurigene Oncology Ltd Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US20240024488A1 (en) * 2020-11-20 2024-01-25 Foghorn Therapeutics Inc. Compounds and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CN117337178A (zh) * 2021-05-10 2024-01-02 福宏治疗公司 化合物及其用途
CR20230518A (es) * 2021-05-10 2024-02-13 Foghorn Therapeutics Inc Compuestos y usos de estos
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
CN115611881B (zh) * 2021-07-13 2024-09-20 复旦大学 一种合成新型vhl配体4-f-vh032的方法
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体
JP2025506452A (ja) * 2022-02-09 2025-03-11 オーリジーン オンコロジー リミテッド Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064328A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof
IL325247A (en) 2023-06-14 2026-02-01 Astrazeneca Ab History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment
PE20260307A1 (es) 2023-06-14 2026-02-11 Astrazeneca Ab Degradadores de smarca2 y usos de estos
CN121816356A (zh) * 2023-07-28 2026-04-07 甘李药业股份有限公司 一种选择性降解smarca2/4的化合物及其应用
CN118406019B (zh) * 2024-07-02 2024-09-20 苏州源起材料科技有限公司 一种噻唑化合物生物医药砌块的合成方法
CN122070278A (zh) * 2024-09-19 2026-05-19 标新生物医药科技(上海)有限公司 含有芳基取代杂芳基的双功能蛋白降解剂及其应用
WO2026120044A1 (en) 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN109152843A (zh) * 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
CA3150354A1 (en) * 2019-09-12 2021-03-18 Muralidhara Ramachandra METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS

Similar Documents

Publication Publication Date Title
JP2021519308A5 (cg-RX-API-DMAC7.html)
EP4422617A1 (en) Combination therapy for treating abnormal cell growth
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
JP2019535744A5 (cg-RX-API-DMAC7.html)
JP2023520333A5 (cg-RX-API-DMAC7.html)
IL265115A (en) Inhibitors of cellular metabolic processes
JP2022071077A5 (cg-RX-API-DMAC7.html)
CN109937041B (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
JP2021512059A5 (cg-RX-API-DMAC7.html)
RU2014151565A (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
JP2019535746A5 (cg-RX-API-DMAC7.html)
JP2014525464A5 (cg-RX-API-DMAC7.html)
JP2017530171A5 (cg-RX-API-DMAC7.html)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2016501221A5 (cg-RX-API-DMAC7.html)
JP2013518089A5 (cg-RX-API-DMAC7.html)
JP2017524668A5 (cg-RX-API-DMAC7.html)
JP2017506250A5 (cg-RX-API-DMAC7.html)
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
JP2014503567A5 (cg-RX-API-DMAC7.html)
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP2014528464A5 (cg-RX-API-DMAC7.html)
ES2877712T3 (es) Terapias combinadas para su uso en el tratamiento del cáncer de mama
JP2016500689A (ja) Hsp90阻害性化合物を用いた、多発性嚢胞腎疾患の治療
WO2018233620A1 (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途